English

ETON PHARMACEUTICALS, INC.

EDGAR

ETON Current report (8-K) · filed 2026-10-14

Annual consolidated revenue for 2025: about USD 79.95M, using the latest reported figures. The previous period, 2024, was about USD 39.01M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

37.6 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 37589000 USD Source

Operating margin

34.04%

2026 Q2 · %

Exact inputs and evidence

Operating Income: 12794000 USD Source
Revenue: 37589000 USD Source

Operating cash flow

7.26 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 14660000 USD Source
Operating Cash Flow: 7405000 USD Source

Cash and cash equivalents: 26.8 million USD 2026-06-30 Source
Exact value

26845000 USD
Long-term debt including current maturities: 30 million USD 2025-03-31 Source
Exact value

29992000 USD
Shares outstanding: 28.3 million shares 2026-06-30 Source
Exact value

28289941 shares

Reported share-count change

5.49% · 1.47 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

26817535 shares · 2025-06-30· Source
28289941 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

106 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 22459000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 79950000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 58669000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 24266000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 37589000 USD · 2026-04-01 – 2026-06-30 Source

Net income

12.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -1927000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -4601000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -6084000 USD · 2025-01-01 – 2025-09-30 Source
Net income: 1554000 USD · 2026-01-01 – 2026-03-31 Source
Net income: 11578000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

15.1 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 22075000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 10049000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 10524000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 22075000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 7405000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: 14660000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: 7405000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

408 thousand USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Capital expenditure: -0 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: -0 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 284000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: -0 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 333000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 284000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 75000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-14.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 6 of 11 periods available· newest 2024-12-31
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+104.9%

Prior period

USD 39.01 million

2024-01-01 – 2024-12-31
Current period

USD 79.95 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

79950000 − 39011000 = 40939000 USD

39011000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
79950000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ETON PHARMACEUTICALS, INC. · 2025-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Year-over-year change in Revenue: 40939000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 79950000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#794870 Filing: 000143774926009059 Input fundies:Revenue: 39011000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#795597 Filing: 000143774926009059
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 778,000

Prior period

−USD 3.82 million

2024-01-01 – 2024-12-31
Current period

−USD 4.6 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-4601000 − -3823000 = -778000 USD

-3823000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-4601000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ETON PHARMACEUTICALS, INC. · 2025-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Year-over-year change in Net income: -778000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -4601000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#1425475 Filing: 000143774926009059 Input fundies:NetIncome: -3823000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#1426174 Filing: 000143774926009059
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+986.1%

Prior period

USD 969,000

2024-01-01 – 2024-12-31
Current period

USD 10.52 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

10524000 − 969000 = 9555000 USD

969000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
10524000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ETON PHARMACEUTICALS, INC. · 2025-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Year-over-year change in Operating cash flow: 9555000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 10524000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#975155 Filing: 000143774926009059 Input fundies:OperatingCashFlow: 969000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#975977 Filing: 000143774926009059
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+1,180.8%

Prior period

USD 26,000

2024-01-01 – 2024-12-31
Current period

USD 333,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

333000 − 26000 = 307000 USD

26000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
333000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ETON PHARMACEUTICALS, INC. · 2025-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Year-over-year change in Capital expenditure: 307000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 333000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#980686 Filing: 000143774926009059 Input fundies:CapitalExpenditure: 26000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#981374 Filing: 000143774926009059
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 79.95 million 100% of revenue
Cost of revenue USD 37.21 million 47% of revenue
Operating expenses USD 43.58 million 55% of revenue
Operating income −USD 844,000 −1.1% of revenue
Tax, interest and other Derived USD 3.76 million 4.7% of revenue
Net income −USD 4.6 million −5.8% of revenue

Cash

Operating cash flow USD 10.52 million 13% of revenue
Capital expenditure USD 333,000 0.4% of revenue
Free cash flow Derived USD 10.19 million 13% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 2,040% of revenue.
2020 Operating loss: operating costs were 69,615% of revenue.
2021 Operating loss: operating costs were 107% of revenue.
2022 Operating loss: operating costs were 139% of revenue.
2023 Operating loss: operating costs were 104% of revenue.
2024 Operating loss: operating costs were 107% of revenue.
2025 Operating loss: operating costs were 101% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	959000	19560000 Derived	-18601000	-281000 Derived	-18320000	-19122000 Derived	Source 2019-01-01 – 2019-12-31: 959000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -18601000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -18320000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -18026000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 1096000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	39000	27150000 Derived	-27111000	859000 Derived	-27970000	-22396000 Derived	Source 2020-01-01 – 2020-12-31: 39000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -27111000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -27970000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -22346000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 50000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	21832000	23327000 Derived	-1495000	460000 Derived	-1955000	-4730000 Derived	Source 2021-01-01 – 2021-12-31: 21832000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -1495000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -1955000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -4721000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 9000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	21251000	29511000 Derived	-8260000	761000 Derived	-9021000	4783000 Derived	Source 2022-01-01 – 2022-12-31: 21251000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -8260000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -9021000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 4821000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 38000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	31642000	32834000 Derived	-1192000	-256000 Derived	-936000	6815000 Derived	Source 2023-01-01 – 2023-12-31: 31642000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -1192000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -936000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: 6815000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: -0 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	39011000	41608000 Derived	-2597000	1226000 Derived	-3823000	943000 Derived	Source 2024-01-01 – 2024-12-31: 39011000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -2597000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -3823000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: 969000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 26000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	79950000	80794000 Derived	-844000	3757000 Derived	-4601000	10191000 Derived	Source 2025-01-01 – 2025-12-31: 79950000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -844000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -4601000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: 10524000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 333000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 80M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	959000	Revenue: 959000 Open source
20202020-12-31	Revenue	39000	Revenue: 39000 Open source
20212021-12-31	Revenue	21832000	Revenue: 21832000 Open source
20222022-12-31	Revenue	21251000	Revenue: 21251000 Open source
20232023-12-31	Revenue	31642000	Revenue: 31642000 Open source
20242024-12-31	Revenue	39011000	Revenue: 39011000 Open source
20252025-12-31	Revenue	79950000	Revenue: 79950000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

104.9% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 959000 Open source
20202020-12-31	Year over year	-95.9%	Revenue: 39000 Open source Revenue: 959000 Open source
20212021-12-31	Year over year	55,879.5%	Revenue: 21832000 Open source Revenue: 39000 Open source
20222022-12-31	Year over year	-2.7%	Revenue: 21251000 Open source Revenue: 21832000 Open source
20232023-12-31	Year over year	48.9%	Revenue: 31642000 Open source Revenue: 21251000 Open source
20242024-12-31	Year over year	23.3%	Revenue: 39011000 Open source Revenue: 31642000 Open source
20252025-12-31	Year over year	104.9%	Revenue: 79950000 Open source Revenue: 39011000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1.1% 2025

Net margin -5.8% 2025

Free cash flow margin 12.7% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-1,939.6%	Operating Income: -18601000 Open source Revenue: 959000 Open source
20202020-12-31	Operating margin	-69,515.4%	Operating Income: -27111000 Open source Revenue: 39000 Open source
20212021-12-31	Operating margin	-6.8%	Operating Income: -1495000 Open source Revenue: 21832000 Open source
20222022-12-31	Operating margin	-38.9%	Operating Income: -8260000 Open source Revenue: 21251000 Open source
20232023-12-31	Operating margin	-3.8%	Operating Income: -1192000 Open source Revenue: 31642000 Open source
20242024-12-31	Operating margin	-6.7%	Operating Income: -2597000 Open source Revenue: 39011000 Open source
20252025-12-31	Operating margin	-1.1%	Operating Income: -844000 Open source Revenue: 79950000 Open source
20192019-12-31	Net margin	-1,910.3%	Net Income: -18320000 Open source Revenue: 959000 Open source
20202020-12-31	Net margin	-71,717.9%	Net Income: -27970000 Open source Revenue: 39000 Open source
20212021-12-31	Net margin	-9%	Net Income: -1955000 Open source Revenue: 21832000 Open source
20222022-12-31	Net margin	-42.4%	Net Income: -9021000 Open source Revenue: 21251000 Open source
20232023-12-31	Net margin	-3%	Net Income: -936000 Open source Revenue: 31642000 Open source
20242024-12-31	Net margin	-9.8%	Net Income: -3823000 Open source Revenue: 39011000 Open source
20252025-12-31	Net margin	-5.8%	Net Income: -4601000 Open source Revenue: 79950000 Open source
20192019-12-31	Free cash flow margin	-1,994%	Revenue: 959000 Open source Operating Cash Flow: -18026000 Open source Capital Expenditure: 1096000 Open source
20202020-12-31	Free cash flow margin	-57,425.6%	Revenue: 39000 Open source Operating Cash Flow: -22346000 Open source Capital Expenditure: 50000 Open source
20212021-12-31	Free cash flow margin	-21.7%	Revenue: 21832000 Open source Operating Cash Flow: -4721000 Open source Capital Expenditure: 9000 Open source
20222022-12-31	Free cash flow margin	22.5%	Revenue: 21251000 Open source Operating Cash Flow: 4821000 Open source Capital Expenditure: 38000 Open source
20232023-12-31	Free cash flow margin	21.5%	Revenue: 31642000 Open source Operating Cash Flow: 6815000 Open source Capital Expenditure: -0 Open source
20242024-12-31	Free cash flow margin	2.4%	Revenue: 39011000 Open source Operating Cash Flow: 969000 Open source Capital Expenditure: 26000 Open source
20252025-12-31	Free cash flow margin	12.7%	Revenue: 79950000 Open source Operating Cash Flow: 10524000 Open source Capital Expenditure: 333000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 10.5M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-18026000	Operating Cash Flow: -18026000 Open source
20202020-12-31	Operating cash flow	-22346000	Operating Cash Flow: -22346000 Open source
20212021-12-31	Operating cash flow	-4721000	Operating Cash Flow: -4721000 Open source
20222022-12-31	Operating cash flow	4821000	Operating Cash Flow: 4821000 Open source
20232023-12-31	Operating cash flow	6815000	Operating Cash Flow: 6815000 Open source
20242024-12-31	Operating cash flow	969000	Operating Cash Flow: 969000 Open source
20252025-12-31	Operating cash flow	10524000	Operating Cash Flow: 10524000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 10.2M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-19122000	Operating Cash Flow: -18026000 Open source Capital Expenditure: 1096000 Open source
20202020-12-31	Free cash flow	-22396000	Operating Cash Flow: -22346000 Open source Capital Expenditure: 50000 Open source
20212021-12-31	Free cash flow	-4730000	Operating Cash Flow: -4721000 Open source Capital Expenditure: 9000 Open source
20222022-12-31	Free cash flow	4783000	Operating Cash Flow: 4821000 Open source Capital Expenditure: 38000 Open source
20232023-12-31	Free cash flow	6815000	Operating Cash Flow: 6815000 Open source Capital Expenditure: -0 Open source
20242024-12-31	Free cash flow	943000	Operating Cash Flow: 969000 Open source Capital Expenditure: 26000 Open source
20252025-12-31	Free cash flow	10191000	Operating Cash Flow: 10524000 Open source Capital Expenditure: 333000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

71.6% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	38.2%	Total Liabilities: 6522000 Open source Total Assets: 17072000 Open source
20202020-12-31	Liabilities / assets	40.5%	Total Liabilities: 10656000 Open source Total Assets: 26319000 Open source
20212021-12-31	Liabilities / assets	35.8%	Total Liabilities: 9835000 Open source Total Assets: 27465000 Open source
20222022-12-31	Liabilities / assets	47.8%	Total Liabilities: 11952000 Open source Total Assets: 25030000 Open source
20232023-12-31	Liabilities / assets	51.2%	Total Liabilities: 16263000 Open source Total Assets: 31740000 Open source
20242024-12-31	Liabilities / assets	67.9%	Total Liabilities: 51695000 Open source Total Assets: 76123000 Open source
20252025-12-31	Liabilities / assets	71.6%	Total Liabilities: 65960000 Open source Total Assets: 92114000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.57× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	7.65×	Current Assets: 15009000 Open source Current Liabilities: 1963000 Open source
20202020-12-31	Current assets / current liabilities	6.51×	Current Assets: 24701000 Open source Current Liabilities: 3794000 Open source
20212021-12-31	Current assets / current liabilities	5.18×	Current Assets: 23604000 Open source Current Liabilities: 4558000 Open source
20222022-12-31	Current assets / current liabilities	3.1×	Current Assets: 20004000 Open source Current Liabilities: 6461000 Open source
20232023-12-31	Current assets / current liabilities	1.65×	Current Assets: 26839000 Open source Current Liabilities: 16241000 Open source
20242024-12-31	Current assets / current liabilities	2.06×	Current Assets: 41021000 Open source Current Liabilities: 19947000 Open source
20252025-12-31	Current assets / current liabilities	1.57×	Current Assets: 60581000 Open source Current Liabilities: 38490000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 12.74 million Exact value Exact value: -12740000 USD 2018-01-01 – 2018-12-31: -12740000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ETON PHARMACEUTICALS, INC. · 2018-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Net Income: -12740000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12740000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315221006122/eton-20201231.xml#178795 Filing: 000149315221006122 The citation records this snapshot. The page link may show a newer release later.	−USD 8.15 million Exact value Exact value: -8145000 USD 2018-01-01 – 2018-12-31: -8145000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ETON PHARMACEUTICALS, INC. · 2018-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Operating Cash Flow: -8145000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8145000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315221006122/eton-20201231.xml#271213 Filing: 000149315221006122 The citation records this snapshot. The page link may show a newer release later.	USD 236,000 Exact value Exact value: 236000 USD 2018-01-01 – 2018-12-31: 236000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ETON PHARMACEUTICALS, INC. · 2018-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Capital Expenditure: 236000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 236000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315221006122/eton-20201231.xml#270655 Filing: 000149315221006122 The citation records this snapshot. The page link may show a newer release later.	−USD 8.38 million Calculation and evidence -8145000 − 236000 USD Exact free cash flow: -8381000 USD 2018-01-01 – 2018-12-31: -8145000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 236000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ETON PHARMACEUTICALS, INC. · 2018-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Free cash flow: -8381000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8145000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315221006122/eton-20201231.xml#271213 Filing: 000149315221006122 Input fundies:CapitalExpenditure: 236000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315221006122/eton-20201231.xml#270655 Filing: 000149315221006122 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 18.32 million Exact value Exact value: -18320000 USD 2019-01-01 – 2019-12-31: -18320000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ETON PHARMACEUTICALS, INC. · 2019-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Net Income: -18320000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18320000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315222006990/form10-k.htm#1680842 Filing: 000149315222006990 The citation records this snapshot. The page link may show a newer release later.	−USD 18.03 million Exact value Exact value: -18026000 USD 2019-01-01 – 2019-12-31: -18026000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ETON PHARMACEUTICALS, INC. · 2019-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Operating Cash Flow: -18026000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18026000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315222006990/form10-k.htm#1262545 Filing: 000149315222006990 The citation records this snapshot. The page link may show a newer release later.	USD 1.1 million Exact value Exact value: 1096000 USD 2019-01-01 – 2019-12-31: 1096000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ETON PHARMACEUTICALS, INC. · 2019-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Capital Expenditure: 1096000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1096000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315222006990/form10-k.htm#1272630 Filing: 000149315222006990 The citation records this snapshot. The page link may show a newer release later.	−USD 19.12 million Calculation and evidence -18026000 − 1096000 USD Exact free cash flow: -19122000 USD 2019-01-01 – 2019-12-31: -18026000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1096000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ETON PHARMACEUTICALS, INC. · 2019-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Free cash flow: -19122000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18026000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315222006990/form10-k.htm#1262545 Filing: 000149315222006990 Input fundies:CapitalExpenditure: 1096000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315222006990/form10-k.htm#1272630 Filing: 000149315222006990 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 27.97 million Exact value Exact value: -27970000 USD 2020-01-01 – 2020-12-31: -27970000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ETON PHARMACEUTICALS, INC. · 2020-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Net Income: -27970000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27970000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315223007933/form10-k.htm#1259979 Filing: 000149315223007933 The citation records this snapshot. The page link may show a newer release later.	−USD 22.35 million Exact value Exact value: -22346000 USD 2020-01-01 – 2020-12-31: -22346000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ETON PHARMACEUTICALS, INC. · 2020-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Operating Cash Flow: -22346000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22346000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315223007933/form10-k.htm#935836 Filing: 000149315223007933 The citation records this snapshot. The page link may show a newer release later.	USD 50,000 Exact value Exact value: 50000 USD 2020-01-01 – 2020-12-31: 50000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ETON PHARMACEUTICALS, INC. · 2020-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Capital Expenditure: 50000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 50000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315223007933/form10-k.htm#939296 Filing: 000149315223007933 The citation records this snapshot. The page link may show a newer release later.	−USD 22.4 million Calculation and evidence -22346000 − 50000 USD Exact free cash flow: -22396000 USD 2020-01-01 – 2020-12-31: -22346000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 50000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ETON PHARMACEUTICALS, INC. · 2020-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Free cash flow: -22396000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22346000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315223007933/form10-k.htm#935836 Filing: 000149315223007933 Input fundies:CapitalExpenditure: 50000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000149315223007933/form10-k.htm#939296 Filing: 000149315223007933 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 1.96 million Exact value Exact value: -1955000 USD 2021-01-01 – 2021-12-31: -1955000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ETON PHARMACEUTICALS, INC. · 2021-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Net Income: -1955000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1955000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774924007853/eton20231231_10k.htm#1191716 Filing: 000143774924007853 The citation records this snapshot. The page link may show a newer release later.	−USD 4.72 million Exact value Exact value: -4721000 USD 2021-01-01 – 2021-12-31: -4721000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ETON PHARMACEUTICALS, INC. · 2021-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Operating Cash Flow: -4721000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4721000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774924007853/eton20231231_10k.htm#872473 Filing: 000143774924007853 The citation records this snapshot. The page link may show a newer release later.	USD 9,000 Exact value Exact value: 9000 USD 2021-01-01 – 2021-12-31: 9000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ETON PHARMACEUTICALS, INC. · 2021-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Capital Expenditure: 9000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774924007853/eton20231231_10k.htm#878533 Filing: 000143774924007853 The citation records this snapshot. The page link may show a newer release later.	−USD 4.73 million Calculation and evidence -4721000 − 9000 USD Exact free cash flow: -4730000 USD 2021-01-01 – 2021-12-31: -4721000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 9000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ETON PHARMACEUTICALS, INC. · 2021-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Free cash flow: -4730000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4721000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774924007853/eton20231231_10k.htm#872473 Filing: 000143774924007853 Input fundies:CapitalExpenditure: 9000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774924007853/eton20231231_10k.htm#878533 Filing: 000143774924007853 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 9.02 million Exact value Exact value: -9021000 USD 2022-01-01 – 2022-12-31: -9021000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ETON PHARMACEUTICALS, INC. · 2022-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Net Income: -9021000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9021000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774925008136/eton20241231_10k.htm#1359595 Filing: 000143774925008136 The citation records this snapshot. The page link may show a newer release later.	USD 4.82 million Exact value Exact value: 4821000 USD 2022-01-01 – 2022-12-31: 4821000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ETON PHARMACEUTICALS, INC. · 2022-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Operating Cash Flow: 4821000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4821000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774925008136/eton20241231_10k.htm#951018 Filing: 000143774925008136 The citation records this snapshot. The page link may show a newer release later.	USD 38,000 Exact value Exact value: 38000 USD 2022-01-01 – 2022-12-31: 38000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ETON PHARMACEUTICALS, INC. · 2022-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Capital Expenditure: 38000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 38000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774925008136/eton20241231_10k.htm#956285 Filing: 000143774925008136 The citation records this snapshot. The page link may show a newer release later.	USD 4.78 million Calculation and evidence 4821000 − 38000 USD Exact free cash flow: 4783000 USD 2022-01-01 – 2022-12-31: 4821000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 38000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ETON PHARMACEUTICALS, INC. · 2022-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Free cash flow: 4783000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 4821000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774925008136/eton20241231_10k.htm#951018 Filing: 000143774925008136 Input fundies:CapitalExpenditure: 38000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774925008136/eton20241231_10k.htm#956285 Filing: 000143774925008136 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 936,000 Exact value Exact value: -936000 USD 2023-01-01 – 2023-12-31: -936000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ETON PHARMACEUTICALS, INC. · 2023-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Net Income: -936000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -936000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#1426873 Filing: 000143774926009059 The citation records this snapshot. The page link may show a newer release later.	USD 6.82 million Exact value Exact value: 6815000 USD 2023-01-01 – 2023-12-31: 6815000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ETON PHARMACEUTICALS, INC. · 2023-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Operating Cash Flow: 6815000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 6815000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#976796 Filing: 000143774926009059 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: -0 USD 2023-01-01 – 2023-12-31: -0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ETON PHARMACEUTICALS, INC. · 2023-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Capital Expenditure: -0 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: -0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#982060 Filing: 000143774926009059 The citation records this snapshot. The page link may show a newer release later.	USD 6.82 million Calculation and evidence 6815000 − -0 USD Exact free cash flow: 6815000 USD 2023-01-01 – 2023-12-31: 6815000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: -0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ETON PHARMACEUTICALS, INC. · 2023-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Free cash flow: 6815000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 6815000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#976796 Filing: 000143774926009059 Input fundies:CapitalExpenditure: -0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#982060 Filing: 000143774926009059 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 3.82 million Exact value Exact value: -3823000 USD 2024-01-01 – 2024-12-31: -3823000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ETON PHARMACEUTICALS, INC. · 2024-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Net Income: -3823000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3823000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#1426174 Filing: 000143774926009059 The citation records this snapshot. The page link may show a newer release later.	USD 969,000 Exact value Exact value: 969000 USD 2024-01-01 – 2024-12-31: 969000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ETON PHARMACEUTICALS, INC. · 2024-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Operating Cash Flow: 969000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 969000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#975977 Filing: 000143774926009059 The citation records this snapshot. The page link may show a newer release later.	USD 26,000 Exact value Exact value: 26000 USD 2024-01-01 – 2024-12-31: 26000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ETON PHARMACEUTICALS, INC. · 2024-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Capital Expenditure: 26000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#981374 Filing: 000143774926009059 The citation records this snapshot. The page link may show a newer release later.	USD 943,000 Calculation and evidence 969000 − 26000 USD Exact free cash flow: 943000 USD 2024-01-01 – 2024-12-31: 969000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 26000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ETON PHARMACEUTICALS, INC. · 2024-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Free cash flow: 943000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 969000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#975977 Filing: 000143774926009059 Input fundies:CapitalExpenditure: 26000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#981374 Filing: 000143774926009059 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 4.6 million Exact value Exact value: -4601000 USD 2025-01-01 – 2025-12-31: -4601000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ETON PHARMACEUTICALS, INC. · 2025-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Net Income: -4601000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4601000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#1425475 Filing: 000143774926009059 The citation records this snapshot. The page link may show a newer release later.	USD 10.52 million Exact value Exact value: 10524000 USD 2025-01-01 – 2025-12-31: 10524000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ETON PHARMACEUTICALS, INC. · 2025-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Operating Cash Flow: 10524000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 10524000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#975155 Filing: 000143774926009059 The citation records this snapshot. The page link may show a newer release later.	USD 333,000 Exact value Exact value: 333000 USD 2025-01-01 – 2025-12-31: 333000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ETON PHARMACEUTICALS, INC. · 2025-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Capital Expenditure: 333000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 333000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#980686 Filing: 000143774926009059 The citation records this snapshot. The page link may show a newer release later.	USD 10.19 million Calculation and evidence 10524000 − 333000 USD Exact free cash flow: 10191000 USD 2025-01-01 – 2025-12-31: 10524000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 333000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ETON PHARMACEUTICALS, INC. · 2025-12-31 ETON PHARMACEUTICALS, INC. (edgar:1710340) Free cash flow: 10191000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1710340?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 10524000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#975155 Filing: 000143774926009059 Input fundies:CapitalExpenditure: 333000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/eton20251231_10k.htm#980686 Filing: 000143774926009059 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

50 filings · 2,389 latest values · 2,389 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001710340, 1710340, ETON, edgar:1710340

Also known as ETON PHARMACEUTICALS, INC., ETON PHARMACEUTICALS, INC., Eton Pharmaceuticals, Inc.

ETON PHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation